ABL Bio

ABL Bio Forward P/E

The Forward P/E Ratio of ABL Bio (298380.KQ) as of Nov 20, 2026 is -269.71. In the previous year, Forward P/E Ratio was -183.63 — a change of 46.88% (lower).

Forward P/E

-269.71

YoY

46.88%

Last updated:

Forward P/E Ratio of ABL Bio is 2025 -269.71 . Forward P/E Ratio of ABL Bio was 2024 -183.63 . It decreases by 46.88% lower compared to the previous year.

The ABL Bio Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-86.98 KRW
Jan 1, 2019
-275.56 KRW
Jan 1, 2020
-183.38 KRW
Jan 1, 2021
-234.10 KRW
Jan 1, 2022
3,177.96 KRW
Jan 1, 2023
-3,852.74 KRW
Jan 1, 2024
-183.63 KRW
Jan 1, 2025
-269.71 KRW
The ABL Bio Forward P/E history
YEARForward P/EYoY
-269.71+46.88%
-183.63-95.23%
-3,852.74-221.23%
3,177.96-1,457.52%
-234.10+27.66%
-183.38-33.45%
-275.56+216.81%
-86.98-36.25%
-136.44-81.69%
-745.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ABL Bio Stock analysis

What does ABL Bio do? ABL Bio, Inc. develops therapeutic drugs for immuno-oncology and neurodegenerative diseases, focusing on anti-angiogenesis antibodies, anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, and antibody-drug conjugates (ADCs). The company generates revenue through the development and commercialization of these advanced biopharmaceutical products, targeting pharmaceutical companies and research institutions seeking innovative treatments for cancer and neurological disorders. Its product portfolio addresses unmet medical needs in oncology and neurology, with a focus on next-generation antibody-based therapies. The company's pipeline includes multiple proprietary drug candidates designed to enhance treatment efficacy and patient outcomes in complex disease areas. ABL Bio, Inc. serves pharmaceutical companies and research institutions as its primary customers, providing them with proprietary antibody technologies and drug candidates for further development and potential commercialization. The company's products are positioned within the immuno-oncology and neurodegenerative disease segments, where demand for targeted therapies is growing. By developing novel antibody-based treatments, ABL Bio aims to capture market share in high-growth therapeutic areas, leveraging its expertise in bispecific and dual-targeting antibody platforms to address complex medical challenges. ABL Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ABL Bio stock

Forward P/E Ratio of ABL Bio is -269.71 in 2025.

Forward P/E Ratio of ABL Bio changed from -183.63 to -269.71, representing a 46.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio ABL Bio since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's ABL Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — ABL Bio

All Key Metrics — ABL Bio